Ramy Sedhom, MD
Hospice and Palliative Medicine · Plainsboro, NJNPI 1124437314
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,925 of the $2,707 with a category attached, or 71.1%. Exelixis Inc. accounts for 83.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $2,425 and has fallen 90.3% since, to $235 in 2025. Among hospice and palliative medicine clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 16 payments — averaging $169.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$2K
- Abiomed$217
- Gilead$83
- Sirtex Medical Inc$50
- AstraZeneca$38
- Puma Biotechnology, Inc.$31
- plus $17 from 1 others
What the payments were for
- Speaking & faculty fees$1,92571%
- Travel & lodging$34613%
- Food & beverage$43616%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 3 | $2,271 |
| Abiomed | 2 | $217 |
| Gilead | 5 | $83 |
| Sirtex Medical Inc | 1 | $50 |
| AstraZeneca | 2 | $38 |
| Puma Biotechnology, Inc. | 2 | $31 |
| GSK | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cabometyx$2,271
How this compares
$2,707 in reported general payments places this provider in the 90th percentile of 38 hospice and palliative medicine providers in New Jersey.
See all hospice and palliative medicine providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZejulaNiraparib Tosylate | 20 | $356,282 |
| TagrissoOsimertinib Mesylate | 21 | $352,572 |
| VerzenioAbemaciclib | 14 | $217,330 |
| XtandiEnzalutamide | 13 | $140,172 |
| CreonLipase/Protease/Amylase | 27 | $96,588 |
| OrgovyxRelugolix | 12 | $30,316 |
| EliquisApixaban | 14 | $9,160 |
| Anastrozole | 205 | $6,942 |
| Exemestane | 11 | $1,630 |
| Dexamethasone | 56 | $567 |
| Sodium Chloride0.9 % Sodium Chloride | 28 | $446 |
| Ondansetron OdtOndansetron | 44 | $435 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 25 | $391 |
| Oxycodone Hcl | 49 | $351 |
| Tamoxifen Citrate | 21 | $283 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKZejula | $17 | $356,28220 claims |
| AstraZenecaTagrisso | $38 | $352,57221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 38 hospice and palliative medicine providers in New Jersey.
Other hospice and palliative medicine in Plainsboro
- Stacey Rifkin-ZenenbergHackensack$19K
- Kenneth AdessaParsippany$16K
- Anjali DesaiMorristown$3K
- Keith PasichowLong Branch$834
- Ilene LauferWest New York$666
- Vandana SharmaNeptune$653
- Christopher BolichCamden$583
- Maria ShindlerMorristown$514
- Felix PachecoParamus$408
- Jose ContrerasHackensack$279
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.